JW Asset Management LLC maintained its position in shares of BioSpecifics Technologies Corp (NASDAQ:BSTC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 73,649 shares of the biopharmaceutical company’s stock at the end of the second quarter. BioSpecifics Technologies Corp comprises 2.3% of JW Asset Management LLC’s portfolio, making the stock its 10th largest position. JW Asset Management LLC owned 1.03% of BioSpecifics Technologies Corp worth $3,646,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Bank of Montreal Can boosted its position in shares of BioSpecifics Technologies Corp by 10.6% in the first quarter. Bank of Montreal Can now owns 7,272 shares of the biopharmaceutical company’s stock worth $398,000 after buying an additional 699 shares during the period. State Street Corp boosted its position in BioSpecifics Technologies Corp by 7.9% in the fourth quarter. State Street Corp now owns 82,092 shares of the biopharmaceutical company’s stock valued at $4,574,000 after buying an additional 5,981 shares during the period. Strs Ohio boosted its position in BioSpecifics Technologies Corp by 161.7% in the first quarter. Strs Ohio now owns 12,300 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 7,600 shares during the period. Cadence Capital Management LLC boosted its position in BioSpecifics Technologies Corp by 22.2% in the first quarter. Cadence Capital Management LLC now owns 26,615 shares of the biopharmaceutical company’s stock valued at $1,459,000 after buying an additional 4,840 shares during the period. Finally, First Manhattan Co. boosted its position in BioSpecifics Technologies Corp by 5.3% in the first quarter. First Manhattan Co. now owns 43,380 shares of the biopharmaceutical company’s stock valued at $1,981,000 after buying an additional 2,200 shares during the period. 54.81% of the stock is currently owned by institutional investors and hedge funds.

BioSpecifics Technologies Corp (NASDAQ:BSTC) opened at 45.31 on Monday. The stock has a market capitalization of $324.60 million, a PE ratio of 27.80 and a beta of 1.76. BioSpecifics Technologies Corp has a 1-year low of $35.79 and a 1-year high of $58.79. The stock’s 50 day moving average price is $49.02 and its 200 day moving average price is $51.60.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/21/biospecifics-technologies-corp-bstc-stake-held-by-jw-asset-management-llc.html.

Several equities analysts have recently issued reports on the company. HC Wainwright set a $72.00 target price on BioSpecifics Technologies Corp and gave the company a “buy” rating in a research note on Thursday, August 10th. BidaskClub cut BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a research note on Friday. Finally, Zacks Investment Research cut BioSpecifics Technologies Corp from a “hold” rating to a “strong sell” rating in a research note on Friday, August 11th.

About BioSpecifics Technologies Corp

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Institutional Ownership by Quarter for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Stock Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related stocks with our FREE daily email newsletter.